Editorial proposes STAMP-F frailty extension to 2026 cardiorenal guidelines
This editorial proposes STAMP-F, an unvalidated conceptual extension of the 2026 European Society of Cardiology cardiorenal guidelines that adds frailty, function and future healthspan to support individualized decisions in older adults. [1]
Automatic summary · not editorially reviewed
The key findings
The 2026 European Society of Cardiology guidelines for cardiovascular disease and chronic kidney disease provide an integrated framework for cardiorenal risk detection, treatment modification and health service planning. [1]
The editorial proposes STAMP-F as a conceptual and currently unvalidated extension of the guideline framework, intended to support individualized decisions rather than serve as an official recommendation, diagnostic criterion or prognostic instrument. [1]
Brief measures such as the Clinical Frailty Scale and gait speed may provide pragmatic entry points for this assessment. [1]
The source at a glance
- Study type / format
- Editorial (abstract)
- Population / context
- Older adults in cardiorenal care, as discussed in an editorial on the 2026 European Society of Cardiology guidelines.
- Summary based on
- Study abstract
- Original publication
- September 8, 2026
Guideline framework and limits of standard measures
The 2026 European Society of Cardiology guidelines for cardiovascular disease and chronic kidney disease offer an integrated framework for cardiorenal risk detection, treatment modification and health service planning. The editorial argues that chronological age, kidney function, albuminuria and conventional cardiovascular risk measures cannot fully capture the clinical heterogeneity of older adults.
Supporting source [1]
Proposed STAMP-F component and suggested brief measures
The editorial proposes STAMP-F as a conceptual and currently unvalidated extension of the guideline framework. The added component stands for Frailty, Function and Future Healthspan and is meant to support individualized decisions, not to serve as an official recommendation, diagnostic criterion or prognostic instrument. Brief measures such as the Clinical Frailty Scale and gait speed are named as possible pragmatic entry points for this assessment.
Supporting source [1]
Treatment balance in older adults and need for prospective studies
Frailty, sarcopenia, cognitive impairment, multimorbidity, polypharmacy and limited life expectancy may substantially change both expected benefits and burdens of treatment. Conversely, the editorial states that advanced age alone should not justify withholding evidence-based cardiorenal therapy from functionally preserved older adults. Incorporating these domains may help align organ-protective treatment with outcomes that matter to older adults, such as mobility, cognition, independence, quality of life and healthspan. Prospective studies are needed to determine whether the approach improves clinical decision-making and patient-centered outcomes.
Supporting source [1]
How to interpret this
This is an abstract of an editorial; the full text was not reviewed. STAMP-F is described as conceptual and currently unvalidated, not an official recommendation, diagnostic criterion or prognostic instrument, and prospective studies are said to be needed.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Martynenko A. · europepmc.org · September 8, 2026